49,294
edits
Difference between revisions of "Quality"
Jump to navigation
Jump to search
→Dealing with diagnostic errors
| (12 intermediate revisions by the same user not shown) | |||
| Line 137: | Line 137: | ||
==Dealing with diagnostic errors== | ==Dealing with diagnostic errors== | ||
* | *Reports that have a diagnostic error should be ''[[Amendment|amended]]''. | ||
*If an addendum would add information to the report that contradicts other information already in the report: it should be an amendment (not an addendum).<ref name=pmid25357114>{{cite journal |authors=Babwah JP, Khalifa M, Rowsell C |title=Analysis of addenda in anatomic pathology as a quality monitoring initiative |journal=Arch Pathol Lab Med |volume=138 |issue=11 |pages=1514–9 |date=November 2014 |pmid=25357114 |doi=10.5858/arpa.2012-0412-OA |url=}}</ref> | |||
It is good practice when amending an report to: | |||
* Clearly state the revised diagnosis. | |||
* Clearly note that the diagnosis was changed. | |||
* Clearly state what the diagnosis was previously. ‡ | |||
* Have another pathologist confirm the revised diagnosis. | |||
* Communicate directly with the most responsible physician - make them aware of the change. | |||
* Document the communication. | |||
‡ It should be noted that: most modern electronic records track all changes. This tracking may or may not be apparent to the end user. Generally, old versions of a report are retrievable. It is good practice to be transparent about a change. | |||
=Measures of quality= | =Measures of quality= | ||
| Line 217: | Line 228: | ||
#Counterstaining. | #Counterstaining. | ||
#Interpretation problem. | #Interpretation problem. | ||
#*Known/expected epitope cross-reactions, e.g. CMV & HSV.<ref name=pmid3029407>{{Cite journal | last1 = Balachandran | first1 = N. | last2 = Oba | first2 = DE. | last3 = Hutt-Fletcher | first3 = LM. | title = Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. | journal = J Virol | volume = 61 | issue = 4 | pages = 1125-35 | month = Apr | year = 1987 | doi = | PMID = 3029407 | PMC = 254073 | | #*Known/expected epitope cross-reactions, e.g. [[CMV]] & [[HSV]].<ref name=pmid3029407>{{Cite journal | last1 = Balachandran | first1 = N. | last2 = Oba | first2 = DE. | last3 = Hutt-Fletcher | first3 = LM. | title = Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. | journal = J Virol | volume = 61 | issue = 4 | pages = 1125-35 | month = Apr | year = 1987 | doi = | PMID = 3029407 | PMC = 254073 | | ||
URL = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC254073/?tool=pubmed }}</ref> | URL = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC254073/?tool=pubmed }}</ref> | ||
#*Unknown/unexpected epitope cross-reactions. | #*Unknown/unexpected epitope cross-reactions. | ||
| Line 300: | Line 311: | ||
Note: | Note: | ||
*Unfortunately one has to shell | *Unfortunately one has to shell out money to get a peak at 'em. | ||
==United States of America== | ==United States of America== | ||
| Line 311: | Line 322: | ||
==Canada== | ==Canada== | ||
===Canadian immunohistochemistry quality control=== | |||
*Abbreviated ''CIQC''. | |||
*[https://ciqc.ca/Pages/default.aspx CIQC webpage (ciqc.ca)] | |||
===Ontario=== | ===Ontario=== | ||
*Quality Management Program - Laboratory Services | *[[Institute for Quality Management in Healthcare]] - previously ''Quality Management Program - Laboratory Services''. | ||
**Set-up by the ''Ontario Medical Assocation''. | **Set-up by the ''Ontario Medical Assocation''. | ||
==United Kingdom== | ==United Kingdom== | ||
| Line 326: | Line 337: | ||
*[[CAP checklists]]. | *[[CAP checklists]]. | ||
*[[Tissue floater]]. | *[[Tissue floater]]. | ||
*[[Histology artifacts]]. | |||
*[[Waffle diagnosis]]. | *[[Waffle diagnosis]]. | ||
*[[Workload measurement]]. | *[[Workload measurement]]. | ||
*[[Anatomical pathology laboratory processes]]. | |||
=References= | =References= | ||